Clinical Trial

A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
THis study aims to evaluate the efficacy of SHR-8068 combined with Adebrelimab and Bevacizumab compared with Sintilimab or Atezolizumab combined with Bevacizumab for the first-line treatment of advanced HCC.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-09-26; most recent amendment 2026-04-28.
Status change: Not Yet Recruiting → Recruiting 2024-11-12
Trial Details
NCT Number NCT06618664
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Advanced Hepatocellular Carcinoma
Enrollment 590 participants
Start Date 2024-10-28
Primary Completion 2026-09 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-04